PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

AI-based breast cancer risk technology receives FDA Breakthrough Device designation

Software developed at WashU Medicine on accelerated path to approval

2025-07-30
(Press-News.org) A new technology that harnesses AI to analyze mammograms and improve the accuracy of predicting a woman’s personalized five-year risk of developing breast cancer has received Breakthrough Device designation from the Food and Drug Administration (FDA). Developed by researchers at Washington University School of Medicine in St. Louis, the software has been licensed to Prognosia Inc., a WashU startup company.

The system analyzes mammograms to produce a risk score estimating the likelihood that a woman will develop breast cancer over the next five years. The technology is compatible with both types of mammogram imaging available: the four 2D views of the breast produced by full-field digital mammography and the synthetic 3D view of the breast produced by digital breast tomosynthesis. Importantly, the system produces an absolute five-year risk that makes it possible to compare a woman’s risk to an average risk based on national breast cancer incidence rates. This provides a meaningful estimate that is aligned with the U.S. national risk reduction guidelines, so that clinicians will know what steps to take next if a woman’s risk is elevated.

The FDA Breakthrough Device designation provides an expedited review process for full market approval in an effort to give patients and clinicians accelerated access to new medical devices. Products that receive the designation have already undergone rigorous testing and shown excellent promise in their potential to improve treatment or the diagnosis of debilitating or life-threatening conditions.

The software package, called Prognosia Breast, was developed by Graham A. Colditz, MD, DrPH, the Niess-Gain Professor of Surgery at WashU Medicine and associate director of prevention and control at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine; and Shu (Joy) Jiang, PhD, an associate professor of surgery in the Division of Public Health Sciences in the Department of Surgery at WashU Medicine. Colditz and Jiang co-founded Prognosia in 2024 in collaboration with WashU’s Office of Technology Management (OTM) and BioGenerator Ventures, the latter of which provided both financial support and business strategy expertise from Entrepreneur-in-Residence David Smoller, PhD.

The software is a pre-trained machine learning system that analyzes mammogram images and provides an estimate of how likely a patient is to develop breast cancer over the next five years, based solely on images and a woman’s age. According to the developers, Prognosia Breast estimates a person’s five-year risk of developing breast cancer 2.2 times more accurately than the standard method, which is based on questionnaires that consider factors such as age, race and family history. The system was trained on past mammograms from tens of thousands of individuals who underwent breast cancer screening through Siteman Cancer Center. Some of them went on to develop cancer, teaching the system what to look for in the earliest stages of tumor development. Such early signs of disease can’t be perceived even by a well-trained human eye.

“We’re excited about the potential of this technology to improve risk prediction and prevention of breast cancer broadly, no matter where a woman is getting screened,” Colditz said. “The long-term goal is to make this technology available to any woman having a screening mammogram anywhere in the world. No matter the type of imaging they receive, our data show the software’s potential to identify women at increased risk of developing breast cancer over the next five years, providing them with opportunities to take targeted steps to reduce that risk.”

The new device could have a large impact on risk prediction because the infrastructure is already in place to begin immediately using the software anywhere mammography is provided. Furthermore, many women already receive regular mammograms. According to 2023 survey data from the Centers for Disease Control and Prevention, more than 75% of women ages 50 to 74 reported having received a mammogram in the past two years.

Even with widespread screening, about 34% of breast cancer patients in the U.S. are diagnosed at later stages of the disease. According to the investigators, being able to assess risk up to five years in advance of the onset of cancer is likely to improve early detection, reducing the number of late-stage cancers diagnosed. Early detection has been shown to make treatment more effective and reduce deaths from breast cancer.

“Receiving a Breakthrough Device designation is a powerful validation of the extraordinary dedication and vision of this research team to improve breast cancer diagnosis and care,” said Doug E. Frantz, PhD, vice chancellor for innovation and commercialization at WashU. “It takes years of concerted effort to produce software that could quickly be integrated into the workflow of any mammography center, significantly enhancing the clinical value of routine mammograms no matter where they are provided. This is a prime example of the vital role of entrepreneurship and commercialization at WashU in transforming cutting-edge research into real-world technologies that improve patient care.”

The device produces a five-year risk score that is intended to complement, not replace, the analysis provided by radiologists, who will continue to review the mammograms following standard protocols. According to the American Society of Clinical Oncology and the U.S. Preventive Services Task Force, a five-year risk score of 3% or higher is considered elevated. According to guidelines from these organizations, women with elevated scores should be referred to specialists who can further advise them on their options for additional screening and prevention strategies.

About one in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. Those found to be at elevated risk of this cancer have the option to receive more frequent screening — which may include other types of imaging, such as MRI — and in some cases may choose to take a type of chemotherapy called tamoxifen or endocrine therapy as preventive treatments. With such options available, identifying women at high risk is important so they have access to specialists who can help guide them in making these important choices.

The developers are planning a clinical trial at Siteman Cancer Center that will apply the risk score from Prognosia Breast in combination with the standard mammography screening protocols. Standard screening protocols include the review of mammograms and measures of breast density already provided to all patients. Individuals found to be at elevated risk will be referred to Siteman’s breast health specialists, who focus on helping individuals navigate the options they have for managing high breast cancer risk.

“Despite the sophistication of today’s breast imaging and its broad use for identifying existing tumors, today’s risk prediction for breast cancer is still questionnaire-based and not very good at estimating future risk,” Jiang said. “Our work has focused on filling that need for better methods. Moving to image-based risk prediction — which our studies have shown is much more accurate — has the potential to be revolutionary for patient care.”

The current FDA designation applies to the software’s analysis of mammogram images taken at a single time point. In the future, the researchers plan to update Prognosia Breast to analyze several years of mammograms from the same individual, which may further improve the accuracy of the prediction.

About Washington University School of Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,900 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,900 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children’s hospitals — the academic hospitals of BJC HealthCare — and treat patients at BJC’s community hospitals in our region. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

END


ELSE PRESS RELEASES FROM THIS DATE:

Young men with passive approach to news tend to believe medical misinformation

2025-07-30
True or false? “It is safe to take an over-the-counter medicine to help you sleep, even if you are drunk on alcohol.” “Driving while high on THC (cannabis) is safe.” “Using psychedelics is safe for everyone.” None of those statements is true. But young men who take a passive approach to news and information—consuming whatever flows over their social media transoms—were likely to believe them in a national survey conducted by Washington State ...

Announcing Zuber Lawler as a Sponsor of ARDD 2025

2025-07-30
The University of Copenhagen is excited to announce Zuber Lawler as a Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online. “Zuber Lawler demonstrates meticulous attention to detail with a client-first mentality… They offer personalized care from highly intelligent and creative counsel… ...

Is this what 2,500-year-old honey looks like?

2025-07-30
Decades ago, archaeologists discovered a sticky substance in a copper jar in an ancient Greek shrine. And until recently, the identity of the residue was still murky — is it a mixture of fats, oils and beeswax or something else? Researchers publishing in the Journal of the American Chemical Society have reanalyzed samples of the residue using modern analytical techniques and determined that it’s likely the remains of ancient honey — a conclusion previous analyses rejected. Honey was an important substance in the ancient world, sometimes left in shrines as offerings ...

Economic evaluation of wastewater surveillance for COVID-19 testing in long-term care settings

2025-07-30
The COVID-19 pandemic has placed enormous pressure on healthcare systems and economies around the world, with particularly severe impacts on vulnerable groups like residents of long-term care facilities (LTCFs). One key lesson from the pandemic is that early detection and treatment can lower hospitalization and death rates while also cutting medical costs. Wastewater surveillance at treatment plants (WSTPs) has emerged as a low-cost and innovative method to detect outbreaks early. Many developed countries have adopted this approach, ...

Announcing Deep Origin as a sponsor of ARDD 2025

2025-07-30
The University of Copenhagen is excited to announce Deep Origin as the latest tier 3 sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online. Deep Origin is building hybrid mechanistic, physics and AI-based models that help researchers design, test, and filter therapeutics in silico – particularly for challenging disease areas such as aging. ...

Cancer cells ‘power up’ when literally pressed to the limit

2025-07-30
Cancer cells mount an instant, energy‑rich response to being physically squeezed, according to a study published in the journal Nature Communications. The surge of energy is the first reported instance of a defensive mechanism which helps the cells repair DNA damage and survive the crowded environments of the human body. The findings help explain how cancer cells survive complex mechanical gauntlets like crawling through a tumour microenvironment, sliding into porous blood vessels or enduring the battering of the bloodstream. The discovery of the ...

Huge hidden flood bursts through the Greenland ice sheet surface

2025-07-30
A huge flood triggered by the rapid draining of a lake beneath the Greenland ice sheet occurred with such force that it fractured the ice above and burst out across its surface. This phenomenon, observed for the first time in Greenland and detailed in research published today in the journal Nature Geoscience, sheds new light on the destructive potential of meltwater stored beneath the ice sheet. It reveals how, under extreme conditions, water flooding underneath the ice can force its way upwards through the ice and escape at the ice sheet surface. This phenomenon is not considered by numerical models ...

The brain shapes what we feel in real time

2025-07-30
The cerebral cortex processes sensory information via a complex network of neural connections. How are these signals modulated to refine perception? A team from the University of Geneva (UNIGE) has identified a mechanism by which certain thalamic projections target neurons and modify their excitability. This work, published in Nature Communications, reveals a previously unknown form of communication between two regions of the brain, the thalamus and the somatosensory cortex. It could explain why the same sensory stimulus does not always elicit the same sensation ...

New study confirms post-pandemic surge in gut-brain disorders

2025-07-30
Bethesda, MD (July 29, 2025) — A new international study confirmed a significant post-pandemic rise in disorders of gut-brain interaction, including irritable bowel syndrome (IBS) and functional dyspepsia, according to the paper published in Clinical Gastroenterology and Hepatology. Building on prior research, investigators used Rome Foundation diagnostic tools to analyze nationally representative samples from both 2017 and 2023 — offering the first direct, population-level comparison of disorders of gut-brain interaction prevalence before and after the COVID-19 pandemic. Key findings: Overall disorders of gut-brain ...

Through the shot glass, and what can be found in liverworts

2025-07-30
Studying plant vegetative reproduction is key to increasing crop yield and for bioengineering. Kobe University research is making progress on studying the genetic regulation of the process in liverworts, which are ideal model plants and even a candidate for space crops. Potatoes are tubers, ginger is a rhizome, and both are forms of vegetative plant reproduction, in which plants create structures from which genetically identical individuals can emerge. This mode of reproduction is very important for agriculture and horticulture, but there is very little research on the underlying genetic mechanism. Kobe University ...

LAST 30 PRESS RELEASES:

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients

Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock

Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes

High Mountain Asia’s shrinking glaciers linked to monsoon changes

All DRII-ed up: How do plants recover after drought?

Research on stigma says to just ‘shake it off’

Scientists track lightning “pollution” in real time using NASA satellite

Millions of women rely on contraceptives, but new Rice study shows they may do more than just prevent pregnancy

Hot days make for icy weather, Philippine study finds

Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology

World's first clinical trial showing lubiprostone aids kidney function

Capturing language change through the genes

Public trust in elections increases with clear facts

Thawing permafrost raised carbon dioxide levels after the last ice age

New DNA test reveals plants’ hidden climate role

Retinitis pigmentosa mouse models reflect pathobiology of human RP59

Cell’s ‘antenna’ could be key to curing diseases

Tiny ocean partnership between algae and bacteria reveals secrets of evolution

Scientists uncover cellular “toolkit” to reprogram immune cells for cancer therapy

Blocking protein control pathway slows rhabdomyosarcoma growth in mice

2026 Hertz Fellowship Application Now Open

The gut immune system is altered in mouse model of Alzheimer’s, providing a new target for therapeutics

ADHD drugs are being prescribed too quickly to preschoolers

UCLA scientists develop off-the-shelf immunotherapy for metastatic kidney cancer

Extreme heat linked to spike in domestic violence calls in New Orleans, study finds

Mount Sinai-Duke University study identifies DNA variants that increase testosterone production in PCOS patients

Physiology-guided complete revascularization in older patients with myocardial infarction

Metals and sulfate in air pollution mixture may contribute most to asthma hospitalizations

[Press-News.org] AI-based breast cancer risk technology receives FDA Breakthrough Device designation
Software developed at WashU Medicine on accelerated path to approval